Shamus R Carr,Frank Villa Hernandez,Hyoyoung Choo-Wosoba et al.
Shamus R Carr et al.
Background: Thymic epithelial tumors (TETs) are broadly classified into thymomas and thymic carcinomas (TC). These can present with pleural dissemination at diagnosis (TNM stage IVA) or as recurrence. As the benefit of re...
First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials [0.03%]
Ewa Kalinka,Igor Bondarenko,Miranda Gogishvili et al.
Ewa Kalinka et al.
Introduction: Patients with unresectable locally advanced NSCLC who are not candidates for concurrent chemoradiation represent an unmet medical need. We report long-term results for this patient subgroup from two phase II...
Montse Sanchez-Cespedes,William W Lockwood,Kenichi Suda et al.
Montse Sanchez-Cespedes et al.
The discovery of EGFR mutations two decades ago launched an era of rapid development and clinical application of targeted therapies in NSCLC. Today, increasing numbers of targeted therapies against somatic aberrations involving nine differe...
Corrigendum to 'First Central Asian Forum on Lung Cancer' [JTO Clinical and Research Reports Volume 7 Issue 1 (2026) 100898] [0.03%]
Jandos Amankulov,David F Yankelevitz,Amangeldi Mukhamejan et al.
Jandos Amankulov et al.
[This corrects the article DOI: 10.1016/j.jtocrr.2025.100898.]. © 2025 The Authors.
Published Erratum
JTO clinical and research reports. 2025 Dec 24;7(4):100948. DOI:10.1016/j.jtocrr.2025.100948 2025
Matthew Lee,Jialing Liu,Kari J Teigen et al.
Matthew Lee et al.
Introduction: Immune checkpoint inhibitor (ICI) clinical trials generally enroll non-Hispanic White patients at academic or private practice settings. ICI outcomes at safety-net settings and across diverse populations rem...
Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study [0.03%]
Akito Miyazaki,Kinnosuke Matsumoto,Motohiro Tamiya et al.
Akito Miyazaki et al.
Introduction: This study aimed to evaluate the real-world clinical outcomes of pembrolizumab monotherapy in patients with advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 1% to 49%. ...
Louis W J R Dossche,M H T Heuff,A M Heijne den Bak et al.
Louis W J R Dossche et al.
We aimed to synthesize current knowledge on pulmonary malignancies in adults with congenital lung malformations (CLMs), focusing on clinical presentation, treatment approaches, and outcomes. We performed a scoping review according to the Pr...
Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective Study [0.03%]
Elio Adib,Amin H Nassar,Katie N Lee et al.
Elio Adib et al.
Introduction: Approximately 15% to 20% of patients with resectable NSCLC receiving neoadjuvant chemoimmunotherapy on clinical trials cannot proceed to surgery due to disease progression, toxicity, or medical contraindicat...
Brief Report: Multi-Institution Real-World Analysis Evaluating Safety, Efficacy, and ctDNA Dynamics After Tarlatamab in Patients With Previously Treated SCLC and LCNEC [0.03%]
Graeme Fenton,Annie L Zhang,Sharon Zhong et al.
Graeme Fenton et al.
Tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 and CD3 on T cells, has generated impressive treatment response rates in relapsed extensive-stage SCLC and large cell neuroendocrine carcinoma. We performed a retrospecti...
Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC [0.03%]
Shinkichi Takamori,Toshio Shimokawa,Atsushi Osoegawa et al.
Shinkichi Takamori et al.
Introduction: Concurrent chemoradiotherapy (cCRT) is the standard of care for unresectable stage III NSCLC, but whether EGFR mutation is a prognostic factor remains unclear. This study evaluated the efficacy and safety of...